Abstract:The prognosis of glioblastoma, which is the most frequent type of adult‑onset malignant brain tumor, is extremely poor. Therefore, novel therapeutic strategies are needed. Previous studies report that JCI‑20679, which is synthesized based on the structure of naturally occurring acetogenin, inhibits mitochondrial complex I and suppresses the growth of various types of cancer cells. However, the efficacy of JCI‑20679 on glioblastoma stem cells (GSCs) is unknown. The present study demonstrated that JCI‑20679 inhibited the growth of GSCs derived from a transposon system‑mediated murine glioblastoma model more efficiently compared with the growth of differentiation‑induced adherent cells, as determined by a trypan blue staining dye exclusion test. The inhibition of proliferation was accompanied by the blockade of cell‑cycle entry into the S‑phase, as assessed by a BrdU incorporation assay. JCI‑20679 decreased the mitochondrial membrane potential, suppressed the oxygen consumption rate and increased mitochondrial reactive oxygen species generation, indicating that JCI‑20679 inhibited mitochondrial activity. The mitochondrial inhibition was revealed to increase phosphorylated (phospho)‑AMPKα levels and decrease nuclear factor of activated T‑cells 2 (NFATc2) expression, and was accompanied by a decrease in calcineurin phosphatase activity. Depletion of phospho‑AMPKα by knockdown of AMPKβ recovered the JCI‑20679‑mediated decrease in NFATc2 expression levels, as determined by western blotting and reverse transcription‑quantitative PCR analysis. Overexpression of NFATc2 recovered the JCI‑20679‑mediated suppression of proliferation, as determined by a trypan blue staining dye exclusion test. These results suggest that JCI‑20679 inhibited mitochondrial oxidative phosphorylation, which activated AMPK and reduced NFATc2 expression levels. Moreover, systemic administration of JCI‑20679 extended the event‑free survival rate in a mouse model transplanted with GSCs. Overall, these results suggested that JCI‑20679 is a potential novel therapeutic agent against glioblastoma.

γ-Glutamylcyclotransferase is transcriptionally regulated by c-Jun and controls proliferation of glioblastoma stem cells through Notch1 levels

Desert Hedgehog Down-regulation Mediates Inhibition of Proliferation by γ-Glutamylcyclotransferase Knockdown in Murine Glioblastoma Stem Cells

Gamma-glutamylcyclotransferase Promotes the Growth of Human Glioma Cells by Activating Notch-Akt Signaling.

The GGCT and REST positive feedback loop promotes tumor growth in Glioma

Neurotensin Signaling Regulates Stem-Like Traits of Glioblastoma Stem Cells Through Activation of IL-8/CXCR1/STAT3 Pathway.

Overexpression of Cystine/Glutamate Antiporter xCT Correlates with Nutrient Flexibility and ZEB1 Expression in Highly Clonogenic Glioblastoma Stem-like Cells (GSCs)

JCI‑20679 suppresses the proliferation of glioblastoma stem cells by activating AMPK and decreasing NFATc2 expression levels

GCN5 Potentiates Glioma Proliferation and Invasion via STAT3 and AKT Signaling Pathways

Knockdown of GGCT Inhibits Cell Proliferation and Induces Late Apoptosis in Human Gastric Cancer

Inhibition of Notch Signaling Blocks Growth of Glioblastoma Cell Lines and Tumor Neurospheres.

Mechanisms of Tumor Growth Inhibition by Depletion of γ-Glutamylcyclotransferase (GGCT): A Novel Molecular Target for Anticancer Therapy

Dual Inhibition of Src and PLK1 Regulate Stemness and Induce Apoptosis Through Notch1-SOX2 Signaling in EGFRvIII Positive Glioma Stem Cells (Gscs).

Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma.

γ-Glutamylcyclotransferase Knockdown Inhibits Growth of Lung Cancer Cells Through G0/G1 Phase Arrest.

NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma

Γ-Glutamyl Cyclotransferase Contributes to Tumor Progression in High Grade Serous Ovarian Cancer by Regulating Epithelial-Mesenchymal Transition Via Activating PI3K/AKT/mTOR Pathway.

CSNK1D is Associated with Stemness and Invasiveness in Glioblastoma

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter

SC-08 * TRANSCRIPTIONAL AND POST-TRANSLATIONAL REGULATIONS OF C-Myc IN GLIOBLASTOMA STEM CELLS

Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM

CCN1 Promotes Mesenchymal Phenotype Transition Through Activating NF‐κB Signaling Pathway Regulated by S100A8 in Glioma Stem Cells